Catalyst-Free Synthesis, in vitro Biological Evaluation and in silico Molecular Docking Studies on a Series of Tosylurea-linked Heterocyclic Analogues as α-Glucosidase Inhibitors


Here are the Catalyst-Free Synthesis, in vitro Biological Evaluation and in silico Molecular Docking Studies on a Series of Tosylurea-linked Heterocyclic Analogues as α-Glucosidase Inhibitors journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.

Catalyst free ball mill reaction, catalyst freepik, biocatalyst in organic chemical synthesis, synthesis of new catalysts, free science lessons catalysts, advanced catalysis and synthesis, catalyst and solvent free.

Catalyst-Free Synthesis, in vitro Biological Evaluation and in silico Molecular Docking Studies on a Series of Tosylurea-linked Heterocyclic Analogues as α-Glucosidase Inhibitors

Insulin resistance, caused by hyperglycemia, the leading cause of the global prevalence of type 2 diabetes. According to recent WHO statistics, 422 million people worldwide suffer from diabetes. α-Glucosidase inhibitors are effective in improving the metabolic profile of patients with type 2 diabetes. The introduction of green chemistry into chemical society has led to the rapid establishment of organic synthesis without catalyst. Hence, a series of tosylurea-linked heterocyclic analogues C1-C9 were synthesized in catalyst-free conditions and their physical (state, colour, melting point) and spectral (FT-IR, 1H NMR, 13C NMR and ESI-HRMS) properties were determined. All compounds were studied in silico and in vitro experiments to assess their bioactive potential as α-glucosidase inhibitors. The in silico molecular docking studies were conducted using Schrödinger Glide software against human α-glucosidase enzyme target (PBD: 3L4W) to identify the virtual binding profile of compounds C1-C9, respectively in relative comparison to the co-crystallized clinically approved α-glucosidase inhibitor. The in vitro α-glucosidase screening assay was performed to identify the hit molecule among C1-C9, the results were compared with a standard drug, voglibose. The observed in silico and in vitro results were consistent and relatively comparable that identified C7 as bioactive hit that demonstrated most stable binding properties at the target site. The observed activity of C7 is primarily due to the synergistic or addition potential of the pharmacophores pyridine and sulfonylurea hybridized into one molecule. The structural analogues of these pharmacophores were earlier proven with potential α-glucosidase inhibitory properties. © 2025 Asian Publication Corporation. All rights reserved.

Authors : Seelan S.J.; Tharmalingam D.; Suresh V.; Yi V.N.W.; Xin Y.R.; Avupati V.R.

Source : Asian Publication Corporation

Article Information

Year 2025
Type Article
DOI 10.14233/ajchem.2025.32826
ISSN 09707077
Volume 37

You can download the article here


If You have any problem, contact us here


Support Us:

Download Now Buy me a coffee Request Paper Here